Cardium Therapeutics CXM -1.79% announced the addition of a new extra-strength carbohydrate blocker product, Alena (TM), to MedPodium's portfolio of Nutra-Apps lifestyle supplements.
Alena(TM) (Extra-Strength Phase 2® plus ChromeMate®) is a non-prescription, 250 mg sealed capsule dietary supplement that is an all-natural, non-stimulant carbohydrate blocker intended to be taken before carbohydrate-rich meals (including junk food snacks and fast food meals) to help reduce the digestion of dietary starches and assist in weight control when used in conjunction with a sensible diet and exercise program*. The key ingredient of Alena is a custom-formulated white kidney bean extract (Phase 2®), which represents the first carbohydrate blocker shown in multiple clinical studies to slow or delay the digestion and absorption of carbohydrates and to help control blood glucose after eating certain starch-laden foods*. MedPodium's Alena(TM) has also been formulated to include ChromeMate® brand chromium polynicotinate that is intended to help metabolize fat, turn protein into muscle and convert sugar into energy*. Researchers have shown that ChromeMate's oxygen-coordinated niacin-bound chromium complex provides a safe and effective form of chromium available in a dietary supplement*. To learn more about Alena(TM), please visit http://www.medpodium.com/index.php/alena.html.
Alena is formulated using a highly concentrated Phase 2® that is approximately four times more potent than other generally available Phase 2® products and was specifically manufactured for use in MedPodium's easy-to-swallow pharmaceutical grade capsules. Alena temporarily inhibits the alpha-amylase enzyme from digesting complex carbohydrates commonly found in modern diets, thus slowing their absorption and reducing their caloric impact*. Alena works selectively to reduce the uptake of the types of carbohydrates found in many starchy foods, without blocking the absorption of "good" simple carbohydrates such as those derived from vegetables and whole grains*. A scientific dossier of the Phase 2® clinical studies can be accessed at http://www.phase2info.com/pdf/phase2-product-overview.pdf.
"The addition of our new Alena(TM) dietary supplement represents another step toward broadening the Company's MedPodium Nutra-Apps healthy lifestyles brand platform and product portfolio for the influential millennial consumer base as well as other modern consumers," stated Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer. "Our Alena(TM) carbohydrate blocker can be used as part of a formal diet and exercise plan, or whenever temptation leads to consumption of junk food snacks or fast food meals, in order to help manage caloric intake from starchy foods. Also, like our other products, our concentrated clinical strength Alena(TM) formulation allows for small easy-to-swallow, pharmaceutically-sealed and tasteless capsules. Alena(TM) has been custom formulated to offer the highest Phase 2 dosage with the smallest capsule size."
Reinhard added, "We plan to continue to identify and evaluate new or improved nutritional ingredients and formulations from around the world for our MedPodium healthy lifestyle brand platform. MedPodium's goal is to offer a portfolio of pharmaceutical grade and easy-to-use products containing best-in-class key ingredients that address the unique health needs of today's technology-driven society. Once our MedPodium product line expands to critical mass, we plan to market and sell certain products through appropriate entry points in various U.S. retail distribution channels."
MedPodium(TM) is a portfolio of science-based, easy to use Nutra-Apps(TM) lifestyle supplements designed to promote health and well-being in today's increasingly complex work and social environment. The MedPodium healthy lifestyle brand is being developed to feature improved product formulations including easy-to use pills and capsules, fast-acting oral drops and sprays, and innovative transdermal delivery systems. Additional information about MedPodium is located at www.medpodium.com.
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium healthy lifestyle product platform. The Company's lead product candidates include Excellagen(TM) topical gel for wound care management, and Generx® DNA-based angiogenic biologic for patients with coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.